Thermo Fisher Scientific (TMO) Change in Receivables (2009 - 2020)

Thermo Fisher Scientific has disclosed Change in Receivables across 12 years of filings, most recently posting $444.0 million for Q4 2020.

• Quarterly Change in Receivables rose 562.5% year-over-year to $444.0 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $1.3 billion (up 478.67% YoY) and the FY2025 annual result came in at $426.0 million, up 149.12% from the prior year.
• Change in Receivables eased to $444.0 million in Q4 2020, from $663.0 million in the prior quarter.
• Over five years, Change in Receivables peaked at $663.0 million in Q3 2020 and troughed at -$96.0 million in Q4 2019.
• A 5-year average of $130.4 million and a median of $49.6 million in 2016 frame the typical range for Change in Receivables.
• Annual changes were most pronounced in 2016 — Change in Receivables soared 7629.03% — and 2019, when it slumped 230.77%.
• Tracing TMO's Change in Receivables over 5 years: stood at $239.6 million in 2016, then retreated by 16.11% to $201.0 million in 2017, then surged by 50.25% to $302.0 million in 2018, then slumped by 131.79% to -$96.0 million in 2019, then soared by 562.5% to $444.0 million in 2020.
• Business Quant data shows TMO's Change in Receivables at $444.0 million in Q4 2020, $663.0 million in Q3 2020, and -$23.0 million in Q2 2020.